MORAb-022

Morphotek · Phase 1 active Small molecule

At a glance

Generic name	MORAb-022
Sponsor	Morphotek
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MORAb-022 CI brief — competitive landscape report
MORAb-022 updates RSS · CI watch RSS
Morphotek portfolio CI